Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00784537

High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients (HD0801)

Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients

Sponsor: Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Conditions Hodgkin's Lymphoma

Interventions ABVD ABVD and Radiotherapy

Updated 9 times since 2017 Last updated: Feb 7, 2018 Started: Sep 30, 2008 Primary completion: Jan 31, 2015 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hodgkin's Lymphoma, this trial is completed. The trial is conducted by Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte and has accumulated 9 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Jun 2023 [monthly]

Completed PHASE2_PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Mar 2018 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Unknown Status → Completed
Feb 2018 — Mar 2018 [monthly]

Unknown Status PHASE2_PHASE3

Status: Active Not Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Fondazione Italiana Linfomi - ETS

Data source: Fondazione Italiana Linfomi - ETS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aviano, Italy , Bari, Italy , Bologna, Italy , Brescia, Italy , Busto Arsizio, Italy , Cagliari, Italy , Florence, Italy , Ivrea, Italy , Lecce, Italy , Milan, Italy and 14 more locations